---
title: "\"Performance\" JIAYUAN SER's annual net profit rises 14.8 times to 129 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/281166880.md"
description: "JIAYUAN SER announced its 2025 annual performance, with revenue of RMB 821 million, a year-on-year decrease of 4.4%. Net profit was RMB 129 million, a year-on-year increase of 14.8 times; earnings per share were RMB 0.21. No final dividend will be distributed"
datetime: "2026-03-31T10:12:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281166880.md)
  - [en](https://longbridge.com/en/news/281166880.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281166880.md)
---

# "Performance" JIAYUAN SER's annual net profit rises 14.8 times to 129 million yuan

JIAYUAN SER (01153.HK) announced its performance for the fiscal year 2025, with revenue of 821 million RMB (the same below), a year-on-year decrease of 4.4%. Net profit was 129 million RMB, a year-on-year increase of 14.8 times; earnings per share were 0.21 RMB. No final dividend will be distributed

### Related Stocks

- [01153.HK](https://longbridge.com/en/quote/01153.HK.md)

## Related News & Research

- [Faron Pharmaceuticals LTD: Holding(s) In Company](https://longbridge.com/en/news/286725255.md)
- [14:00 ETAn InventHelp 123Invent Client Develops New Sun Visor Attachment](https://longbridge.com/en/news/286951811.md)
- [14:42 ETMondetta Named One of Canada's Best Managed Companies for 2026](https://longbridge.com/en/news/286680393.md)
- [14:00 ETVmake Integrates ICML-Accepted BridgeRemoval Algorithm for Advanced AI Video Object Removal](https://longbridge.com/en/news/287102767.md)
- [03:14 ETDatar Cancer Genetics recibe una histórica aprobación de la FDA estadounidense para CellDx-Tissue](https://longbridge.com/en/news/287174095.md)